A Stable One-Shot COVID Vaccine Is Deemed Safe and Effective

Paul Christian Gordon/Zuma

The coronavirus is a rapidly developing news story, so some of the content in this article might be out of date. Check out our most recent coverage of the coronavirus crisis, and subscribe to the Mother Jones Daily newsletter.

Johnson & Johnson’s one-shot coronavirus vaccine is highly effective at preventing severe disease and death from COVID-19, the Food and Drug Administration found in analyses published today.

An international study found the vaccine’s efficacy rate to be 72 percent in the United States and 64 percent in South Africa, where a more contagious variant is spreading. While these figures are lower than Pfizer’s and Moderna’s efficacy rates, the vaccine greatly reduces the risk of hospitalization and death from COVID-19 and could play a key role in keeping the pandemic at bay. In a clinical trial of 40,000 people, no one who took the vaccine was hospitalized or died of COVID-19 after the vaccine took effect.

Plus, the vaccine requires only one shot and does not need special refrigeration—good news at a time when demand for vaccines greatly outstrips supply.

The FDA could authorize the vaccine for emergency use as early as Saturday, with 20 million doses available by the end of March and a total of 100 million doses delivered by the end of June.

ONE MORE QUICK THING:

Or at least we hope. It’s fall fundraising time, and we’re trying to raise $250,000 to help fund Mother Jones’ journalism during a shorter than normal three-week push.

If you’re reading this, a fundraising pitch at the bottom of an article, you must find our team’s reporting valuable and we hope you’ll consider supporting it with a donation of any amount right now if you can.

It’s really that simple. But if you’d like to read a bit more, our membership lead, Brian Hiatt, has a post for you highlighting some of our newsroom's impressive, impactful work of late—including two big investigations in just one day and covering voting rights the way it needs to be done—that we hope you'll agree is worth supporting.

payment methods

ONE MORE QUICK THING:

Or at least we hope. It’s fall fundraising time, and we’re trying to raise $250,000 to help fund Mother Jones’ journalism during a shorter than normal three-week push.

If you’re reading this, a fundraising pitch at the bottom of an article, you must find our team’s reporting valuable and we hope you’ll consider supporting it with a donation of any amount right now if you can.

It’s really that simple. But if you’d like to read a bit more, our membership lead, Brian Hiatt, has a post for you highlighting some of our newsroom's impressive, impactful work of late—including two big investigations in just one day and covering voting rights the way it needs to be done—that we hope you’ll agree is worth supporting.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate